Fatty liver is diagnosed and risk-stratified in steps: (1) identify liver fat on imaging, (2) assess metabolic risk with basic labs and measurements, (3) estimate fibrosis risk with the FIB-4 blood score, and (4) if FIB-4 is indeterminate or high, measure liver stiffness with elastography (ultrasound shear-wave elastography in our office, or MRE). The aim is to find fibrosis, not just fat.
The idea behind the pathway
Finding fat in the liver is easy and, on its own, not very informative. The decisive question is whether there is fibrosis — scarring — because fibrosis stage, rather than the amount of fat, is what most predicts serious outcomes. The pathway therefore separates finding fat from finding risk, and takes the cheapest and least invasive tests first.
A second principle runs through it: not every patient needs every test. The pathway works as a filter, reassuring the low-risk majority with minimal testing and routing the higher-risk minority to the tests, and the clinicians, that change management. The structure follows AASLD and EASL–EASD–EASO guidance. → What Is MASLD?
STEP 1 — Identify steatosis (is there fat?)
- Ultrasound — the most common first look. Widely available and inexpensive, it shows a "bright" (echogenic) liver when fat is present.
- CT and MRI — often how fat is found incidentally during scans done for other reasons.
- MRI-PDFF (proton density fat fraction) — the most precise, quantitative fat measurement, used mainly in specialist care and research to track change over time.
- UDFF (ultrasound-derived fat fraction) — a fat percentage measured on the same ultrasound used for shear-wave elastography. It tracks closely with MRI-PDFF, and above about 5% indicates steatosis.
Ordinary ultrasound has three limits worth stating plainly. It is insensitive to lower amounts of fat and may miss mild steatosis, it is operator-dependent, and it does not measure fibrosis. A fatty liver reported on ultrasound is a steatosis finding and says nothing about scarring, which is why Step 1 is never the end of the workup. → "My Liver Tests Are Normal…"
STEP 2 — Assess metabolic risk (why is the fat there?)
MASLD is metabolic disease, so the second step characterizes the metabolic driver — both to confirm that the diagnosis is metabolic and because these findings shape treatment. The information is routine and low-cost:
- BMI and waist circumference — overall and central adiposity. → BMI, Body Fat & Body Composition
- Blood pressure.
- A1c and fasting glucose — for diabetes or prediabetes.
- Lipid panel, especially triglycerides and HDL.
- Liver enzymes (ALT/AST) — useful context, but not a fibrosis test.
- Renal function and a medication review — some drugs affect the liver or the interpretation of tests, and comorbidities influence management.
This step also screens for other or contributing liver disease — alcohol intake, viral hepatitis where relevant, other causes — so the diagnosis is not assumed to be metabolic by default. → Who Should Be Evaluated?
STEP 3 — Assess fibrosis risk (FIB-4 first)
The first-line answer to the scarring question comes from FIB-4, a score calculated from four routine values — age, AST, ALT and platelet count — that most people already have.
FIB-4 cutoffs (standard adult interpretation):
| FIB-4 | Category | Meaning | Next step |
|---|---|---|---|
| < 1.3 | Low risk | Advanced fibrosis unlikely (strong rule-out) | Manage metabolic risk; recheck periodically |
| 1.3 – 2.67 | Indeterminate | Can't classify on FIB-4 alone | Second-line test (elastography) |
| > 2.67 | High risk | Higher likelihood of advanced fibrosis | Elastography and/or hepatology referral |
The age caveat is essential. FIB-4 puts age in the numerator, so scores drift upward with age regardless of true fibrosis. In adults aged ≥65, the lower cutoff is raised to about 2.0 to cut down false positives, so a value of 1.3–2.0 in a 70-year-old is often not treated as indeterminate. FIB-4 also performs less well in people under about 35. A low FIB-4 is genuinely reassuring; a high one is a flag rather than a diagnosis. → FIB-4 Explained
STEP 4 — Second-line noninvasive testing (measure stiffness)
When FIB-4 is indeterminate or high, or other features raise concern, the next step measures liver stiffness, a physical surrogate for fibrosis.
- Ultrasound shear-wave elastography (ARFI) — performed in the office on the Siemens ACUSON Sequoia: a quick, painless ultrasound exam reporting liver stiffness in kilopascals (kPa) or m/s, where higher stiffness suggests more fibrosis. As a MASLD rule of thumb for this technique, <7 kPa is low and reassuring, 7–9 kPa suggests mild-to-moderate fibrosis, and ≥9 kPa raises concern for advanced fibrosis (≥13 kPa suggests cirrhosis). The same exam measures fat by UDFF, and the two numbers answer different questions: kPa = fibrosis surrogate; UDFF = fat. Stand-alone transient elastography (FibroScan) uses different cutoffs, roughly 8 and 12 kPa.
- MRE (magnetic resonance elastography) — MRI-based stiffness mapping, more accurate than ultrasound elastography and less affected by body habitus, but costlier and less available. Reserved for uncertain or discordant cases.
Elastography is a surrogate rather than a biopsy. It measures stiffness, which usually tracks fibrosis but can be distorted by obesity or probe fit, by recent food, or by liver congestion. Only a minority of patients reach this step, and fewer still need biopsy. → Elastography & Liver Fat · Liver Biopsy: When It's Needed
The pathway, as a flow
| Stage | Test | Question answered |
|---|---|---|
| Metabolic risk | Diabetes, obesity, metabolic syndrome | Who to evaluate |
| Steatosis (Step 1) | Ultrasound / CT / MRI / MRI-PDFF / UDFF | Is there fat? |
| Stratification (Step 3) | FIB-4 — age, AST, ALT, platelets; age-adjusted ≥65 | How likely is advanced fibrosis? |
| Second line (Step 4) | Shear-wave elastography (kPa) or MRE, when FIB-4 is indeterminate or high | How stiff is the liver? |
| Lower risk | Monitor | Treat metabolic risk; recheck periodically |
| Intermediate risk | Intervene | Address the metabolic disease actively; reassess fibrosis |
| Higher risk | Refer / further evaluate | Hepatology involvement, consideration of MASH therapy, and selectively biopsy → MASH Medications |
Step 2, the metabolic-risk assessment, runs alongside the others, characterizing the driver and guiding treatment at every stage.
Not every patient needs every test
Both over- and under-testing are common. A metabolically healthy person with a low FIB-4 does not need liver elastography, an MRE or a biopsy. A person with diabetes and metabolic syndrome should not be reassured by normal enzymes and a bright liver on ultrasound alone, since normal ALT and AST do not rule out fibrosis. The pathway matches the intensity of testing to the probability of at-risk disease, checked against AASLD and EASL–EASD–EASO recommendations.
What the evidence says: the diagnostic pathway
- What we know: a stepwise noninvasive pathway — identify steatosis, assess metabolic risk, FIB-4, then elastography — risk-stratifies most people without biopsy. FIB-4 has an excellent low-risk rule-out, and elastography adds accuracy for the indeterminate and high groups.
- What we think: in our practice this sequence is the right default — cheap first, invasive last, biopsy rarely.
- What we don't know: optimal re-testing intervals, and the best pathway for "lean" MASLD and for some discordant cases.
- What patients can expect: a sequence rather than a single test, and an answer framed as a position on fibrosis risk rather than a yes-or-no on fatty liver. → FIB-4 Explained
Where a particular patient falls on that pathway, and which of the four steps the workup should actually include, is what an individual assessment at the practice establishes.
Questions patients ask
How is fatty liver diagnosed?
In steps: find liver fat on imaging, assess metabolic risk with basic labs, estimate fibrosis risk with FIB-4, and, if FIB-4 is indeterminate or high, measure liver stiffness with elastography. The aim is to find fibrosis, not just fat. Grade A 🟢
Can an ultrasound tell whether there is liver scarring?
No. Ordinary ultrasound detects fat, not fibrosis, and it can even miss mild fat. Scarring is assessed with FIB-4 and elastography. Grade A 🟢
What is the difference between UDFF and kPa on liver elastography?
UDFF (ultrasound-derived fat fraction) estimates liver fat, while the kPa stiffness number is a fibrosis surrogate. One ultrasound elastography exam reports both, and they answer different questions. Grade A 🟢 → Elastography & Liver Fat
Why does age change the FIB-4 interpretation?
Age sits in the FIB-4 formula, so scores rise with age regardless of true fibrosis. At 65 and older, a higher lower cutoff of about 2.0 is used to reduce false positives. Grade A 🟢 → FIB-4 Explained
Is liver elastography needed in every case?
No — only when FIB-4 is indeterminate or high, or other features raise concern. Many people are risk-stratified by FIB-4 alone. Grade A 🟢
Is a liver biopsy needed to diagnose fatty liver?
Usually not. The noninvasive pathway of FIB-4 followed by elastography stratifies most people, and biopsy is reserved for selected uncertain cases. Grade A 🟢 → Liver Biopsy: When It's Needed
Written by Darius A. Schneider, MD, PhD · Board-Certified Endocrinologist (ECNU) · Last updated: Oct 2026 · References: AASLD Practice Guidance on MASLD (2023); EASL–EASD–EASO clinical practice guidance; guideline-based FIB-4 cutoffs (<1.3 / >2.67; age-adjusted ~2.0 at ≥65). Educational; not a diagnosis.
